Zelira Therapeutics Ltd has released a press release.
Quarterly Activities/Appendix 4C Cash Flow Report
Earlier from Zelira Therapeutics
- Transformative US$33M Fundraising into Zeliras HOPE 1 SPV
- Zelira receives $1,070,000 R&D Tax Incentive Scheme Refund
- Preliminary Final Report
- Zelira Therapeutics Secures R&D Loan Facility